May 8, 2008
NEW
YORK (Reuters Health) - Thromboembolic events are increased in patients
undergoing lenalidomide-based therapy for multiple myeloma, US and
Italian researchers report. Aspirin prophylaxis appears to reduce this
risk.
Along
with lenalidomide-based therapy, 52 received high-dose dexamethasone
(40 mg 12 days a month) and 73 received prednisolone or dexamethasone
40 mg, 4 times per month. In addition, 110 were given
thromboprophylactic treatment, primarily aspirin.
Overall,
10 patients (8%) developed deep vein thrombosis (DVT), the
investigators report in the April 1st issue of Cancer. Four were not
receiving thromboprophylactic treatment at the time of the event.
Post new comment